The primary outcome of our GWAS meta-analysis is log-transformed eGFRcrea. This was used by the studies contributing to the CKDGen meta-analyses and for our UKB association analysis. In UKB, creatinine was measured in serum by enzymatic analysis on a Beckman Coulter AU5800 (UKB data field 30700, http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=30700) and GFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula53 (link),54 (link). For all studies involved in the CKDGen analysis, creatinine concentrations were measured in serum and GFR was estimated based on the CKD-EPI (for individuals >18 years of age)53 (link),54 (link) or the Schwartz (for individuals <= 18 years of age)55 (link) formula. Details on the study-specific measurements for the CKDGen studies were described previously7 (link). For all studies, eGFRcrea was winsorized at 15 or 200 ml/min/1.73 m2 and winsorized eGFRcrea values were log-transformed using a natural logarithm. Secondary outcomes used for downstream analyses include log-transformed eGFRcys and log-transformed BUN. In UKB, cystatin C was measured based on latex enhanced immunoturbidimetric analysis on a Siemens ADVIA 1800 (UKB data field 30720, http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=30720) and blood urea was measured by GLDH, kinetic analysis on a Beckman Coulter AU5800 (UKB data field 30670, http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=30670). Details on the cystatin C and blood urea measurements in CKDGen studies can be found in the previous work7 (link),13 (link). In CKDGen and UKB, eGFRcys was obtained from cystatin C measurements using the formula by Stevens et al.56 (link) or the CKD-EPI formula53 (link),54 (link), respectively. In all studies, eGFRcys was winsorized at 15 or 200 ml/min/1.73 m2 and winsorized eGFRcys values were log-transformed using a natural logarithm. Blood urea measurements in mg/dL were multiplied by 2.8 to obtain BUN values, which were then log-transformed using a natural logarithm.
Free full text: Click here